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Abstract
Aims
To determine the effects of glucagon-like peptide-1 receptor agonists compared with pla-
cebo and other anti-diabetic agents on weight loss in overweight or obese patients with type
2 diabetes mellitus.
Methods
Electronic searches were conducted for randomised controlled trials that compared a gluca-
gon-like peptide-1 receptor agonist therapy at a clinically relevant dose with a comparator
treatment (other type 2 diabetes treatment or placebo) in adults with type 2 diabetes and a
mean body mass index 25kg/m2. Pair-wise meta-analyses and mixed treatment compari-
sons were conducted to examine the difference in weight change at six months between the
glucagon-like peptide-1 receptor agonists and each comparator.
Results
In the mixed treatment comparison (27 trials), the glucagon-like peptide-1 receptor agonists
were the most successful in terms of weight loss; exenatide 2mg/week: -1.62kg (95% CrI:
-2.95kg, -0.30kg), exenatide 20μg: -1.37kg (95% CI: -222kg, -0.52kg), liraglutide 1.2mg:
-1.01kg (95%CrI: -2.41kg, 0.38kg) and liraglutide 1.8mg: -1.51 kg (95% CI: -2.67kg,
-0.37kg) compared with placebo. There were no differences between the GLP-1 receptor
agonists in terms of weight loss.
Conclusions
This review provides evidence that glucagon-like peptide-1 receptor agonist therapies are
associated with weight loss in overweight or obese patients with type 2 diabetes with no
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Introduction
TheWorld Health Organisation estimates that over 1.4 billion adults were overweight in 2008,
and of these 500 million were obese [1]. Obesity (defined as a body mass index30kg/m2)
increases the risk of developing type 2 diabetes mellitus, a condition where blood glucose levels
are elevated due to decreased insulin production and/or sensitivity. It is estimated that there
are 347 million people with diabetes worldwide [2]; type 2 diabetes accounts for between 85–
95% of these cases. The relationship between obesity and increased risk of major complications
in type 2 diabetes, including mortality is well documented [3] and concerning given the current
increasing rates of obesity. Weight reduction is a key intervention for people with type 2 diabe-
tes [4]. When diet and lifestyle modifications have not elicited improvements in glycaemic con-
trol the first-line treatment for type 2 diabetes is metformin, with further therapies being added
as necessary, including sulfonylureas, thiazolidinediones, GLP-1 receptor agonists and DPP-IV
inhibitors [4]. Unfortunately, not all of these therapies are weight neutral and some can lead to
weight gain [5]. A review of GLP-1 receptor agonists showed that these can lead to weight loss
in obese or overweight patients with type 2 diabetes [6]. Exenatide, liraglutide and lixisenatide
are GLP-1 receptor agonists that are currently used treatments for overweight patients with
type 2 diabetes.
A traditional pair-wise meta-analysis has been conducted in this area, comparing data from
two GLP-1 receptor agonists combined (exenatide and liraglutide) against a control [6].
Grouping exenatide and liraglutide may not be the best approach as they are different drugs;
for example, exenatide has a 50% amino acid homology to GLP-1 whereas liraglutide has a
97% homology and thus a longer half-life. Furthermore, they are administered with different
frequencies. Therefore, they may have different effects on weight loss. In order to examine the
different effects of the GLP-1 receptor agonist therapies on weight loss, a mixed treatment
comparison meta-analysis was performed to estimate the treatment effects of each intervention
individually. Mixed treatment comparison meta-analyses allow direct and indirect evidence to
be combined, allowing treatment comparisons where no head-to-head trials exist through a
common comparator.
Materials and Methods
Literature search and inclusion criteria
We identified publications published up to June 2013 from searches of Medline and Embase.
The search strategy used free text terms and keywords to identify randomised controlled trials
assessing GLP-1 receptor agonist therapies that reported a weight change (an example search
strategy is given in S1 File). The titles and abstracts of all studies identified by the electronic
searches were screened for inclusion by one reviewer (JP). The full texts of all studies found to
be potentially relevant were assessed by three individuals (JP, DB and LG).
We included studies meeting the following inclusion criteria: 1) randomised controlled trial,
2) published in English language, 3) adult participants (age 16 years) with type 2 diabetes, 4)
mean body mass index of all participants in the study 25kg/m2, 5) at least one licensed GLP-
1 receptor agonist therapy treatment arm administered for 6 months at a dose given in clinical
practice in the UK, and 6) weight reported as an outcome at six months, as this was the most
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common time reported. Studies in adults without type 2 diabetes were excluded since there
were too few studies in that population to allow for a meaningful evidence synthesis. There
were no restrictions placed on the treatment given to the control group. Neither were restric-
tions placed on any other oral anti-diabetic treatments the participants may already be receiv-
ing. Studies comparing two different GLP-1 receptor agonist therapies were also included. The
reference lists of pooled or secondary analyses were hand searched for papers that were eligible
for inclusion, although no additional papers were identified through this method.
Data extraction and quality assessment
Data extraction was performed on the full texts that were eligible for inclusion by three individ-
uals (JP, DB, and LG), who used a standard data extraction template. Any issues found with
the information that studies reported were discussed and checked by a second individual. The
following data were extracted: author, year of publication, journal of publication, study coun-
try, number of treatment arms, type of treatment, treatment duration, interventions received,
time points when data were collected, number of withdrawals, and number lost to follow-up, as
well as mean body mass index, mean age and percentage of female participants for each treat-
ment arm. Information was also extracted on the mean weight (kg) and standard deviation
(SD) at baseline and 6 months (we allowed the mean follow up to vary between 4–8 months
post randomisation), and/or the change in mean weight and SD of each treatment arm, which-
ever was reported in the trial. Some papers also reported the difference between the treatment
arms which was extracted if arm level data were not reported. The quality of the studies was
assessed by looking at the main areas in which bias can occur in the study: randomisation of
the treatments, allocation concealment, blinding of the study, and the flow of participants.
Statistical analysis
For studies that had given clinically relevant doses of the treatments for six months, a pair-wise
meta-analysis was carried out followed by a mixed treatment comparison meta-analysis. As all
patients had type 2 diabetes it was assumed that they would all be receiving similar background
treatments and so the interventions were simplified by ignoring the background treatments. As
well as this, the dose for the non GLP-1 receptor agonist treatments was ignored. Where SDs
for means were not reported, these were estimated from standard errors, ranges, p-values or
95% confidence intervals as appropriate [7]. Where data on baseline and follow-up weight
were reported, the mean change was calculated and the SD was imputed [7]. Any SD less than
one was assumed to have been misreported and assumed to be a standard error (n = 4 [8–11]).
The pair-wise meta-analyses pooled studies in Stata Version 12 using a random effects
model as studies were expected to be heterogeneous. Heterogeneity was assessed using the I2
statistic. Publication bias was assessed visually using contour enhanced funnel plots [12] for all
comparisons that contained five or more studies.
Mixed treatment comparison methods were used to compare all interventions under inves-
tigation within a single model. There was a continuous outcome of mean change in body
weight from baseline between treatments. Placebo was used as the reference category through-
out. A random effects mixed treatment comparison meta-analysis was conducted using a linear
regression model adjusting for the fact that some trials had more than two treatment arms
[13]. The model was fitted with a burn in of 10,000 samples which were discarded, followed by
20,000 samples that were recorded. For each treatment, the percentage of times that the treat-
ment gained the highest rank across all of the simulations was calculated. Sensitivity to the
length of burn in, sample size and initial values was examined. Convergence of the initial values
was checked by Brooks-Gelman-Rubin plots [14]. History plots were used to assess whether
Glucagon-Like Peptide 1 Receptor Agonists andWeight Loss
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the length of burn in and sample size were adequate. The residual deviance was used to assess
model fit with the residual deviance for a good fitting model lying around the number of
unconstrained data points. All mixed treatment comparison analyses were conducted using a
Markov chain Monte Carlo simulation method in WinBUGS 1.4.3, with vague prior
distributions.
The results of the pair-wise meta-analysis and the mixed treatment comparison were com-
pared for inconsistencies in the mean differences calculated by each method. The results were
defined to be inconsistent if the estimate calculated by the mixed treatment comparison did
not fall in the 95% confidence interval calculated from the pair-wise analysis.
Results
Study Characteristics
Searches identified 1327 records from the electronic databases for inclusion in the systematic
review (Fig 1). After removing 381 duplicate records, 946 titles and abstracts were screened. The
initial screening process found that 792 records were not suitable for inclusion. Full texts were
assessed for the remaining 154 records. There were 127 records excluded leaving 27 studies that
fulfilled the inclusion criteria and had data extracted for inclusion in the meta-analyses (Fig 1).
In the 27 trials, 16 different interventions were given, and there were 31 direct comparisons
reported between the different interventions (Fig 2). The GLP-1 receptor agonist therapies
included were exenatide 20μg daily, exenatide 2mg/week, liraglutide 1.2mg daily and liraglutide
1.8mg daily. Lixisenatide was not included because no eligible studies considering this treat-
ment were identified in the review process. Control interventions included placebo and metfor-
min among others (Fig 2). According to the inclusion criteria, all included trials reported a
mean body mass index of> 25kg/m2 (range 25.8kg/m2–35.0kg/m2). The age of participants
ranged from 51 years to 60 years. The minimum percentage of females included was 29.7%
ranging up to trials where 63% of the participants were female (Table 1).
Quality assessment
Out of the 27 studies that were eligible for inclusion, 93% provided the details of the randomi-
sation process (S1 Table). Only 19% of trials gave information on the allocation process and
19% also recorded the double blinding of the study with adequate information. For the flow of
participants, 85% provided full details of participants.
Evidence Synthesis
From the pair-wise analysis, exenatide 20μg, liraglutide 1.2mg and liraglutide 1.8mg all had
mean weight losses significantly greater than placebo of 1.32kg (95% CI 0.21kg, 2.43kg; n = 7
studies), 1.31kg (95% CI 0.77kg, 1.85kg; n = 2 studies) and 1.70kg (95% CI 0.80kg, 2.60kg;
n = 3 studies) respectively. The difference in weight loss between exenatide 20μg and exenatide
2mg/week was small and non-significant: 0.05kg (95% CI -1.17kg, 1.27kg; n = 3 studies) as was
the weight loss between liraglutide 1.2mg and liraglutide 1.8mg: 0.43kg (95% CI -0.1kg, 1.0kg;
n = 3 studies). Liraglutide 1.8mg had a slightly greater weight loss that exenatide 20μg, 0.3kg
(95% CI -0.60kg, 1.2kg; n = studies) which was once again not significant. There were no direct
comparisons between exenatide 2mg/week and placebo, liraglutide 1.2mg or liraglutide 1.8mg.
Neither was there a direct comparisons between exenatide 20μg and liraglutide 1.2mg.
In the mixed treatment comparison, the three GLP-1 receptor agonist treatments all showed
a greater mean weight loss than placebo (exenatide 20μg: -1.37kg (95% Credible Interval (CrI)
-2.22kg, -0.52kg); exenatide 2mg/week: -1.62kg (95% CrI -2.95kg, -0.30kg); liraglutide 1.2mg:
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-01.01kg (95% CrI -2.41kg, 0.38kg); liraglutide 1.8mg -1.51kg(95% CrI -2.67kg, -0.37kg). The
weight loss seen with liraglutide 1.2mg was non-significant, however all the others saw signifi-
cant weight loss and ranked as the best treatments (Table 2). Differences in average weight loss
between the GLP-1 receptor agonists were small and non-significant (liraglutide 1.2mg vs exe-
natide 20μg: -0.36kg (95% CrI -1.83kg, 1.10kg); liraglutide 1.2mg vs exenatide 2mg/week:
-0.61kg (95%CrI -2.32kg, 1.06kg); liraglutide 1.2mg vs liraglutide 1.8mg: -0.50kg (95% CrI
-0.80kg, 1.78kg); exenatide 20μg vs exenatide 2mg/week: -0.25kg, (95% CrI -0.78kg, 1.28kg);
Fig 1. PRISMA flow diagram of study selection.
doi:10.1371/journal.pone.0126769.g001
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exenatide 20μg vs liraglutide 1.8mg: -0.15kg (95% CrI -1.08kg, 1.38kg); exenatide 2mg/week vs
liraglutide 1.8mg: -0.11kg (95%CrI -1.63kg, 1.41kg)).
Model diagnostics
The I2 statistic was larger than 75% for four comparisons in the analysis (exenatide 20μg vs pla-
cebo, insulin glargine and exenatide 2mg/week, as well as pioglitazone vs exenatide 2mg/week
and sitagliptin). Due to a limited number of direct comparisons, the I2 statistic could not be cal-
culated for several comparisons. The mixed treatment comparison estimated the between trial
variance to be 1.28 (95% CrI 0.58, 2.56), which supports the heterogeneity in the pair-wise
meta-analysis.
There were seven inconsistencies where the mixed treatment comparison and pair-wise
meta-analysis results differed substantially; namely, exenatide 2mg/week vs insulin glargine,
exenatide 2mg/week vs metformin, exenatide 20μg vs metformin, liraglutide 1.2mg vs pioglita-
zone, liraglutide 1.8mg vs pioglitazone, pioglitazone vs insulin detemir and pioglitazone vs
metformin. A contour enhanced funnel plot of the comparison between placebo and exenatide
20μg was produced as this was the only comparison for which more than five studies were
included (S1 Fig). There is some indication that studies in the area of statistical non-signifi-
cance may be missing systematically, thus publication bias may be present.
The model had a good level of fit as the total residual deviance values (61.5) was close to the
number of unconstrained data points (60). The between trial variance for the analysis was 1.28
(95% CrI 0.59, 2.56) which does suggest there is heterogeneity present.
Fig 2. Network diagram of treatments comparisons in analysis.Numbers represent the number of studies that reported a direct comparison between
each pair of treatments. Line thickness is weighted so that a thicker line represents a higher number of direct comparisons.
doi:10.1371/journal.pone.0126769.g002
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Table 1. Summary of included trials.
Author
(year)
Interventions Country Number of
participants
Treatment
Duration
(months)
Mean
BMI
(kg/
m2)
Mean
Age
(years
Females
(%)
Background
Treatment
Apovian
(2010) [23]
Exenatide 20μg USA 96 5.5 33.6 54.5 63 Pharmaceutical
Placebo 98 5.5 33.9 55.1 62 Pharmaceutical
Bergenstal
(2009) [24]
Exenatide 20μg USA 124 5.5 34.2 52.5 51.6 Pharmaceutical
Biphasic Insulin
aspart
248 5.5 33.6 52.4 52 Pharmaceutical
Bergenstal
(2010) [25]
Exenatide 2mg/
week
USA, India, Mexico 170 6 32 52 44 Pharmaceutical
Sitagliptin 100mg 172 6 32 52 48 Pharmaceutical
Pioglitazone 45mg 172 6 32 53 52 Pharmaceutical
Blevins
(2011) [8]
Exenatide 20μg USA 123 5.5 33 55 45 Pharmaceutical
Exenatide 2mg/
week
129 5.5 33.6 56 40 Pharmaceutical
Buse (2011)
[26]
Exenatide 20μg Greece, Israel, Mexico, 137 6.9 33.8 59 49 Pharmaceutical
Placebo UK, USA 122 6.9 33.1 59 36 Pharmaceutical
Buse (2004)
[9]
Exenatide 20μg USA 125 6.9 33 56 42.6 Pharmaceutical
Placebo 123 6.9 34 55 37.4 Pharmaceutical
Buse (2009)
[43]
Exenatide 20μg Austria, Denmark, Finland,
France, Germany, Ireland,
Macedonia, Norway, Poland,
Puerto Rico, Romania,
Slovenia, Spain, Sweden,
Switzerland, USA
231 6 32.9 57.1 45 Pharmaceutical
Liraglutide 1.8mg 233 6 32.9 56.3 51 Pharmaceutical
Davies
(2013) [27]
Exenatide 2mg/
week
UK 111 6 33.7 59 36 Pharmaceutical
Insulin detemir 105 6 33.7 58 31 Pharmaceutical
Davies
(2009) [28]
Exenatide 20μg UK 118 6 34.6 56.8 29.7 Pharmaceutical
Insulin glargine 117 6 33.7 56.2 33.6 Pharmaceutical
DeFronzo
(2010) [29]
Exenatide 20μg USA 45 4.6 32.5 56 49 Non-
Pharmaceutical
Exenatide 20μg
+ Rosiglitazone
8mg
47 4.6 32.5 56 49 Non-
Pharmaceutical
Rosiglitazone 8mg 45 4.6 32.5 56 49 Non-
Pharmaceutical
DeFronzo
(2005) [30]
Placebo USA 113 6.9 34 54 40.7 Pharmaceutical
Exenatide 20μg 113 6.9 34 52 39.8 Pharmaceutical
Derosa
(2010) [31]
Exenatide 20μg Italy 63 6 28.7 57 52.4 Pharmaceutical
Glibenclamide
15mg
65 6 28.5 56 49.2 Pharmaceutical
Derosa
(2011) [32]
Exenatide 20μg Italy 57 6 28.4 56 50.9 Pharmaceutical
Glimepiride 6mg 54 6 28.5 55 51.9 Pharmaceutical
DeVries
(2011) [44]
Insulin Detemir
+ Liraglutide
1.8mg
Belgium, Canada, France,
Germany, Italy, Netherlands,
Spain, UK, USA
162 6 34.9 56.8 45.7 Pharmaceutical
Liraglutide 1.8mg 161 6 33.9 57.3 44.7 Pharmaceutical
Diamant
(2010) [33]
Exenatide 2mg/
week
USA, Puerto Rico, European
Union, Russia, Australia,
Republic of Korea, Taiwan,
Mexico
233 6 32 58 48 Pharmaceutical
Insulin glargine 223 6 32 58 45 Pharmaceutical
(Continued)
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Table 1. (Continued)
Author
(year)
Interventions Country Number of
participants
Treatment
Duration
(months)
Mean
BMI
(kg/
m2)
Mean
Age
(years
Females
(%)
Background
Treatment
Drucker
(2008) [34]
Exenatide 2mg/
week
USA, Canada 148 7.5 35 55 45 Pharmaceutical
Exenatide 20μg 147 7.5 35 55 49 Pharmaceutical
Heine (2005)
[35]
Exenatide 20μg Australia, Belgium, Brazil,
Finland, USA, Germany,
Netherlands, Poland, Norway
Puerto Rico, Portugal, Spain,
Sweden
282 6 31.4 59.8 45 Pharmaceutical
Insulin glargine 267 6 31.3 58 43.4 Pharmaceutical
Ji (2013) [11] Exenatide 2mg/
week
China, India, Japan, South
Korea, Taiwan
340 6 26.4 55 46.2 Pharmaceutical
Exenatide 20μg 338 6 26.7 56 45.6 Pharmaceutical
Kadowaki
(2011) [36]
Placebo Japan 36 6 25.8 56.3 31.4 Pharmaceutical
Exenatide 20μg 73 6 25.8 59.4 31.9 Pharmaceutical
Kendall
(2005) [37]
Placebo USA 247 7.5 34 56 44.1 Pharmaceutical
Exenatide 20μg 241 7.5 34 55 40.7 Pharmaceutical
Liutkus
(2010) [38]
Exenatide 20μg Canada, Mexico, Romania,
South Africa, USA
111 6 34 55 40 Pharmaceutical
Placebo 54 6 33 54 43 Pharmaceutical
Nauck
(2009) [10]
Liraglutide 1.2mg Argentina, Australia, Belgium,
Bulgaria, Croatia, Denmark,
Germany, Hungary, India,
Ireland, Italy, Netherlands,
New Zealand, Norway,
Romania, Russia, Slovakia,
South Africa, Spain, Sweden,
UK
240 24 31.1 57 46 Pharmaceutical
Liraglutide 1.8mg 242 6 30.9 57 46 Pharmaceutical
Glimepiride 4mg 242 24 31.2 57 43 Pharmaceutical
Placebo 121 24 31.6 56 40 Pharmaceutical
Pratley
(2010) [39]
Liraglutide 1.2mg Croatia, Germany, Ireland,
Italy, Netherlands, Romania,
Serbia, Slovakia, Slovenia,
Spain, UK
221 6 32.6 55.9 48 Non-
Pharmaceutical
Liraglutide 1.8mg 218 6 33.1 55 48 Non-
Pharmaceutical
Sitagliptin 100mg 219 6 32.6 55 45 Non-
Pharmaceutical
Russell
Jones (2009)
[45]
Liraglutide 1.8mg USA, Argentina, Belgium,
Brazil, UK, Canada, France,
Germany, Hungary, India,
Israel, Italy, Republic of
Korea, Mexico, Poland, Puerto
Rico, Romania, Slovakia,
South Africa, Spain, Turkey
230 6 30.4 57.6 43 Pharmaceutical
Placebo 114 6 31.3 57.5 51 Pharmaceutical
Insulin Glargine 232 6 30.3 57.5 40 Pharmaceutical
Russell-
Jones (2012)
[40]
Exenatide 2mg/
week
USA, Argentina, Belgium,
Brazil, UK, Canada, France,
Germany, Hungary, India,
Israel, Italy, Republic of
Korea, Mexico, Poland, Puerto
Rico, Romania, Slovakia,
South Africa, Spain, Turkey
248 6 31.4 51 44 Non-
Pharmaceutical
Metformin
2000mg
246 6 30.7 54 37.4 Non-
Pharmaceutical
Pioglitazone 45mg 163 6 31.1 55 40.5 Non-
Pharmaceutical
Sitagliptin 100mg 163 6 31.8 52 42.3 Non-
Pharmaceutical
Yuan (2012)
[41]
Exenatide 20μg China 33 6 30.6 58.5 49 Non-
Pharmaceutical
Metformin
1500mg
26 6 29.3 56.8 54 Non-
Pharmaceutical
(Continued)
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Discussion
A pair-wise meta-analysis and mixed treatment comparison found that the GLP-1 receptor
agonist therapies considered resulted in a reduction in body weight; these reductions were only
significant in some analyses. Differences in average weight loss between the GLP-1 receptor
agonists were small and non-significant
These findings add to evidence that GLP-1 receptor agonists may have weight loss benefits
in patients with type 2 diabetes. These weight loss effects have been shown previously [17], and
it is believed that GLP-1 receptor agonists affect weight loss through their effects on appetite
and satiety [18]. GLP-1 is a gut hormone secreted from the lower intestinal endocrine L-cells
following the ingestion of food. It has a number of functions which include augmenting insu-
lin’s response to glucose, slowing gastric emptying, suppressing the secretion of glucagon and
thus hepatic glucose output, and increasing satiety. Our findings further suggest that weight
loss effects may differ between the GLP-1 receptor agonists, possibly due to the different
homologies of the drugs and the different frequencies with which they are administered. Inter-
estingly the level of weight loss seen was consistent across BMI (S2 Fig).
In previous systematic reviews and meta-analyses of GLP-1 receptor agonist therapies,
weight change is usually not the primary outcome and so is not well reported. Instead, the meta-
analyses primarily look at the effect of these therapies on other outcome measures, such as
HbA1c, on which they have a positive effect [19]. There has only been one meta-analysis of
Table 1. (Continued)
Author
(year)
Interventions Country Number of
participants
Treatment
Duration
(months)
Mean
BMI
(kg/
m2)
Mean
Age
(years
Females
(%)
Background
Treatment
Zinman
(2009) [42]
Liraglutide 1.2mg USA, Canada 178 6 33.2 55 43 Pharmaceutical
Liraglutide 1.8mg 178 6 33.5 55 49 Pharmaceutical
Placebo 177 6 33.5 55 49 Pharmaceutical
doi:10.1371/journal.pone.0126769.t001
Table 2. Results of Mixed Treatment Comparison.
Treatment Rank (95% CrI) Probability best treatment (%) Mean weight change compared with placebo (kg) (95% CrI)
Exenatide 2mg 3 (1, 6) 26.04 -1.62 (-2.95, -0.30)
Liraglutide 1.8mg 3 (1, 6) 19.76 -1.51 (-2.67, -0.37)
Exenatide 20μg 4 (1, 6) 6.45 -1.37 (-2.22, -0.52)
Liraglutide 1.2mg 5 (1, 8) 5.83 -1.01 (-2.41, 0.38)
Sitagliptin 5 (1, 10) 14.72 -0.88 (-3.31, 1.63)
Metformin 5 (1, 9) 8.54 -0.95 (-2.75, 0.86)
Insulin Detemir + Liraglutide 1.8 mg 6 (1, 11) 14.17 -0.71 (-3.33, 1.99)
Placebo 8 (5, 10) 0.02 —
Exenatide 20μg + Rosiglitazone 8 (1, 13) 4.45 0.25 (-2.54, 3.00)
Insulin Detemir 11 (8, 15) 0.01 1.85 (-0.06, 3.79)
Glimepiride 11 (9, 15) 0.00 1.93 (0.30, 3.54)
Pioglitazone 11 (9, 15) 0.00 1.99 (0.18, 3.84)
Rosiglitazone 13 (9, 16) 0.02 2.94 (0.17, 5.69)
Insulin Glargine 14 (11, 16) 0.00 3.12 (1.47, 4.78)
Glibenclamide 15 (10, 16) 0.01 3.83 (1.25, 6.40)
Biphasic Insulin Aspart 15 (11, 16) 0.00 4.04 (1.49, 6.60)
doi:10.1371/journal.pone.0126769.t002
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weight loss for GLP-1 receptor agonist therapies (exenatide or liraglutide at a clinically relevant
dose), which found that they were associated with a greater weight loss than control intervention
(-2.9kg; 95% CI -3.6kg, -2.2kg) [6]. The control intervention was a pooled group of placebo and
other treatments. This weight loss was also seen in the subgroup of participants with type 2 dia-
betes (-2.8kg; 95% CI -3.4kg, -2.3kg). Other studies also support the results of this mixed treat-
ment comparison analysis, but do not show the difference in weight loss between the GLP-1
receptor agonist treatments. These include a pooled analysis of phase three trials from the Lira-
glutide Effect and Action in Diabetes (LEAD) program, which found a statistically significant
reduction in body weight for liraglutide 1.2mg versus placebo across different age groups [20],
and a pooled analysis looking at the efficacy and tolerability of exenatide once weekly, which
found that it was significantly associated with reduced body weight, taking into account the
baseline glucose lowering therapy that the patient was already receiving [21]. The average weight
loss observed in the current analysis was lower than in the previous meta-analysis at -1.01kg for
liraglutide 1.2mg, -1.51kg for liraglutide 1.8mg, -1.37kg for exenatide 20μg and -1.62kg for exe-
natide 2mg/week. Though these amounts are small, they are likely to confer some clinical benefit
since it has been shown that, on average, each 1kg of weight loss is associated with 3–4 months
additional survival in people with type 2 diabetes [22]. Furthermore, the other anti-diabetes
medications considered were all associated with weight gain on average, albeit not always signif-
icantly so, highlighting the weight loss benefits of the GLP-1 receptor agonists, and it might be
that longer treatment durations would have resulted in greater weight loss.
The previous pair-wise review included studies of people with type 2 diabetes and those
without type 2 diabetes [6], three studies were conducted in those without type 2 diabetes. A
comparable weight loss was seen to those conducted in people with type 2 diabetes. We did not
include studies conducted in people without type 2 diabetes. Given the limited evidence base
for those without diabetes future research should focus on whether GLP-1 receptor agonists
can be used for weight loss in those who are free from type 2 diabetes but overweight or obese.
The risk of bias was assessed in the trials included in the analysis. Most studies were able to
account for the participants who dropped out with detailed information, and there was ade-
quate reporting on randomisation. The percentage of trials reporting double blinding was quite
small (19%), suggesting bias might have been introduced. The lack of blinding is probably a
result of the interventions being delivered differently; GLP-1 receptor agonist therapies and
insulin are injectables and all other therapies are administered orally. The outcome is weight
which can be recorded accurately and objectively at any stage of the trial, and should not be
influenced by an investigator, therefore the effect of non-blinding is likely to be minimal. Publi-
cation bias may have been present with non-significant studies appearing to be less likely to be
published. This might mean that the published literature is biased towards showing a weight
loss effect of GLP-1 receptor agonists.
The mixed treatment comparison allowed direct and indirect evidence to be included in a
single evidence synthesis while preserving the randomisation. This also allowed the GLP-1
therapies to be analysed separately instead of combined, meaning that no assumption was
made about the similarity of the behaviour of the GLP-1 receptor agonist therapies. The back-
ground treatment was ignored, making the assumption that any treatment given alongside the
primary intervention or the control did not affect the behaviour of the intervention or alter the
weight change seen. This was done to make the trials more comparable, to simplify the treat-
ments given and to limit the number of interventions considered. It is seen that different classes
of interventions give different weight changes. This could suggest that this assumption may not
be valid, and that the weight change seen may be exaggerated or limited if given with a back-
ground treatment which produces a weight loss or gain. This limits the analysis as it assumes
that all the background treatments behave in the same way and it may have been more useful
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to stratify the pharmaceutical interventions into the different types of anti-diabetic medication
given to account for their different effects on weight.
The mixed treatment comparison analyses allows treatments to ranked in terms of the prob-
ability that they are best treatment. Exenatide 2mg/week appeared to be the best treatment out
of the GLP-1 receptor agonists as it was ranked higher than exenatide 20μg and liraglutide
1.8mg, though the differences in weight loss between the treatments were small and non-signif-
icant. With the exception of liraglutide 1.2mg the GLP-1 receptor agonist therapies considered
ranked higher than the comparator treatments. These results should be interpreted with cau-
tion though as recent work by Kibret et al [46] showed that the rank probability is sensitive to
various factors including unequal numbers of studies in the comparisons and whether network
contains loops, both of which appear in our network.
A major strength of this work is that the systematic review conducted was extensive, using
all licenced GLP-1 receptor agonist therapies, so it was unlikely that trials of interest were
missed. Due to there being no eligible studies using lixisenatide at the time of the review, only
the effects of liraglutide and exenatide were considered. The GLP-1 therapies were considered
at clinically relevant doses which makes the research relevant to clinical practice, even though
one dose liraglutide 1.8mg is not recommended for use in the UK [16]. A limitation was that
full text searching and data extraction were done by three individuals (JP, DB and LG). How-
ever discussions were had so that the information included was consistent to avoid bias. GLP-1
receptor agonist therapies are associated with side effects including nausea, diarrhoea, head-
aches, dizziness and vomiting. These side effects may escalate the amount of weight loss, and
so further investigation needs to be conducted to look at the adverse events to see whether
there are unacceptable levels of adverse events, which outweigh the weight loss benefits in par-
ticipants. The review was conducted following the guidelines of the PRISMA statement (S2
File). Further work may also be needed to attempt to explain heterogeneity seen by adding
study level covariates into the model in order to adjust for potentially unevenly distributed
covariates between trials [15].
In conclusion, the analyses undertaken provide evidence that treatment with GLP-1 recep-
tor agonist therapies for 6 months was associated with a reduction in body weight in partici-
pants who are overweight or obese with type 2 diabetes. There is no clear evidence as to which
GLP-1 receptor agonist leads to the greatest weight loss, although our analyses may suggest
that exenatide is superior to liraglutide, although more data is required to confirm this. Further
investigation needs to be conducted to determine the effects of GLP-1 receptor agonist therapy
in people without diabetes who are overweight or obese.
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